Second-line with @entity1311 and @entity3003 for XXXX following first @entity1311 and @entity902 compounds in @entity43 .

@entity43 @entity1 @entity66 @entity3003 @entity1311 @entity902
OBJECTIVE: The combination of @entity1311 and @entity902 compounds is considered the best first-line regimen for advanced @entity43 . The purpose of this study was to evaluate a @entity1311 and @entity3003 combination in pretreated @entity1 who recurred within 24 months after a complete clinical response with the same regimen used as first-line chemotherapy. METHODS: 18 @entity1 were included in this study. Second-line chemotherapy consisted of @entity1311 , 175 mg/m2 as a 3-hour infusion, and @entity3003 AUC 6 every 21 days. RESULTS: Among 15 evaluable @entity1 , eight (53%) complete and five (34%) partial responses were observed, while two (13%) @entity1 had @entity66 ( @entity66 ). The response rate was 67% among @entity1 with measurable disease and 52% for evaluable disease. The median progression-free interval after second-line chemotherapy was 8.3 months. The median progression-free interval for @entity1 with measurable disease was 8.6 months and for evaluable disease it was 7.9 months. Seven (46%) of 15 @entity1 have developed recurrence after second-line chemotherapy with @entity1311 and @entity3003 with a median time to recurrence of 9.8 months. CONCLUSION: @entity1311 175 mg/m2 and @entity3003 AUC 6 as second-line chemotherapy in this sensitive population is effective in terms of response rate and progression-free interval.
